Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to Buy

Key Points

• Wall Street Zen upgraded Zimmer Biomet (ZBH) from "hold" to "buy" on Saturday, and TD Cowen has also upgraded the stock, but the consensus rating remains a Hold with a $106.20 average price target.
• Quarterly beat and guidance: ZBH reported $2.42 EPS vs. $2.38 expected and $2.24B revenue (up 10.9% YoY), and issued FY2026 guidance of $8.30–$8.45 EPS versus analyst expectations of $8.22.
• Shares opened at $93.14 with a market cap of $18.03B and a 1‑year range of $84.59–$108.29; SVP Lori Winkler sold 2,650 shares (~$250,849) and institutional investors own about 88.9% of the stock.

Zimmer Biomet (NYSE:ZBH - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday. BTIG Research reiterated a "neutral" rating on shares of Zimmer Biomet in a report on Monday, March 23rd. UBS Group reiterated a "sell" rating and set a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. William Blair assumed coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They issued a "market perform" rating on the stock. Finally, TD Cowen upgraded shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a report on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $106.20.

Zimmer Biomet Stock Up 0.1%

Shares of Zimmer Biomet stock opened at $93.14 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $108.29. The firm's 50-day moving average is $92.92 and its two-hundred day moving average is $93.43. The stock has a market cap of $18.03 billion, a price-to-earnings ratio of 26.31, a PEG ratio of 1.90 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to analysts' expectations of $2.22 billion. During the same period in the prior year, the business earned $2.31 EPS. The firm's quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the firm's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company's stock.

Institutional Trading of Zimmer Biomet

Institutional investors have recently bought and sold shares of the stock. Rakuten Investment Management Inc. purchased a new position in shares of Zimmer Biomet during the 3rd quarter valued at approximately $37,307,000. Sector Gamma AS increased its holdings in shares of Zimmer Biomet by 28.0% during the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider's stock valued at $11,178,000 after purchasing an additional 24,847 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider's stock valued at $6,019,000 after purchasing an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd grew its stake in Zimmer Biomet by 6.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider's stock valued at $35,506,000 after acquiring an additional 22,104 shares during the period. Finally, National Pension Service grew its stake in Zimmer Biomet by 4.5% in the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider's stock valued at $38,757,000 after acquiring an additional 16,928 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.